Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study
Dermatology · 2023 · 239 (1) · 52-59
DOI: 10.1159/000526019 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Dermatology, online erschienen am 23.08.2022. Verfasst von Manuel Sánchez-Díaz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle which presents with painful nodules, abscesses, and fistulae in apocrine gland-bearing areas of the skin. Approved treatments include antibiotics and biologic drugs such as adalimumab. Despite these treatments, HS management is challenging. Acitretin is an oral retinoid used for its management as 3rd or 4th line therapy. There is little evidence regarding the effectiveness and safety of acitretin treatment for HS, and no reports have previously explored the potential clinical predictors associated with the response to the treatment.
Methods
Retrospective cohort study to assess the effectiveness and safety of acitretin treatment in HS patients who failed to respond to topical therapies.
Results
Sixty-two patients with moderate to severe HS were included. A significant decrease in the International HS Severity Scoring System (IHS4) score was found over time. Higher basal IHS4 score, family history of HS, follicular phenotype, and history of follicular plugging conditions were potential predictors of response. Most patients did not suffer any adverse events, and no severe side effects were observed. The main cause of discontinuation was lack of efficacy.
Conclusion
Acitretin can be considered as a therapeutic option for patients with HS. The presence of follicular phenotype or a history of components of follicular occlusion syndrome is associated with better outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, Hospital Universitario Virgen de las Nieves, IBS Granada, Granada, Spain.
- Dermatology Department, School of Medicine, University of Granada, Granada, Spain.
- Hidradenitis Suppurativa Clinic, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Zitieren
APA
Sánchez-Díaz, M., Díaz-Calvillo, P., Rodríguez-Pozo, J. Á., Arias-Santiago, S., & Molina-Leyva, A. (2023). Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study. Dermatology, 239(1), 52-59. https://doi.org/10.1159/000526019
Vancouver
Sánchez-Díaz M, Díaz-Calvillo P, Rodríguez-Pozo JÁ, Arias-Santiago S, Molina-Leyva A. Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study. Dermatology. 2023;239(1):52-59. doi:10.1159/000526019
BibTeX
@article{SnchezDaz2023,
author = {Sánchez-Díaz, Manuel and Díaz-Calvillo, Pablo and Rodríguez-Pozo, Juan Ángel and Arias-Santiago, Salvador and Molina-Leyva, Alejandro},
title = {Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study},
journal = {Dermatology},
year = {2023},
volume = {239},
number = {1},
pages = {52--59},
doi = {10.1159/000526019}
}
EUVIMED